#### Edgar Filing: Cunnane Deirdre A. - Form 4

Cunnane D	Deirdre A.									
Form 4 September	11 2018									
								OMB A	PPROVAL	
FORI	UNITE	) STATES					COMMISSION		3235-0287	
Washington, D.C. 20549Check this box if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWNER 					nge Act of 1934, of 1935 or Sectio	Expires: January 31 2009 Estimated average burden hours per response 0.5				
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> Cunnane Deirdre A.			2. Issuer Name and Ticker or Trading Symbol CATABASIS PHARMACEUTICALS INC [CATB]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
	(First) ABASIS CEUTICALS, IN L SQ, BLDG 140			of Earliest T Day/Year) 2018	ransaction		X Officer (give below) Chie	e title Oth below) ef Legal Office	er (specify r	
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			ıl	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
CAMBRI	DGE, MA 02139						Person	viole mail one R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)		ned 1 Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities I Beneficially ( Owned (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: R	eport on a separate lin	ne for each c	lass of sec	urities benef	-	-	or indirectly.	tion of	SEC 1474	
							ained in this form		(9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

required to respond unless the form displays a currently valid OMB control

### **Reporting Owners**

#### Edgar Filing: Cunnane Deirdre A. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and 4	ecurities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.71	09/07/2018		А	150,000	<u>(1)</u>	09/06/2028	Common Stock	150,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships				
	Director	10% Owner	Officer	Other	
Cunnane Deirdre A. C/O CATABASIS PHARMACEUTICALS, INC. ONE KENDALL SQ, BLDG 1400E, STE B14202 CAMBRIDGE, MA 02139			Chief Legal Officer		

## Signatures

/s/ Deirdre A. Cunnane	09/10/2018		
<u>**</u> Signature of Reporting Person	Date		

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option was granted on September 7, 2018 and is subject to vesting over a two year period, with 50% of the shares vesting on the first anniversary of September 7, 2018 and the remainder vesting over the ensuing year at a rate of 4.1667% per month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.